Evidence map›Paper›PMID 32805181›Full record

Observational studyJournal of the American Heart Association2020

Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.

Heidi S Wirtz, Richard Sheer, Narimon Honarpour, Adrianne W Casebeer, Jeff D Simmons, Christopher E Kurtz, Margaret K Pasquale, Gary Globe

Abstract readObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Systematic Literature Review of the Impact of Type 2 Diabetes and Heart Failure Guideline Adherence on Clinical and Economic Outcomes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  9. Review
  10. Review
  11. Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Comorbidities and determinants of health on heart failure guideline-directed medical therapy adherence: All of us.International journal of cardiology. Cardiovascular risk and prevention · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heidi S WirtzAmgen Inc. Thousand Oaks CA.
Richard SheerHumana Healthcare Research Inc. Louisville KY.
Narimon HonarpourAmgen Inc. Thousand Oaks CA.
Adrianne W CasebeerHumana Healthcare Research Inc. Louisville KY.
Jeff D SimmonsHumana Inc. Louisville KY.
Christopher E KurtzAmgen Inc. Thousand Oaks CA.
Margaret K PasqualeHumana Healthcare Research Inc. Louisville KY.
Gary GlobeAmgen Inc. Thousand Oaks CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF-related hospitalization using the Humana Medicare Advantage database (2008-2016). HF medication classes (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none [23% of patients; n=3987], monotherapy [22%; n=3777], dual therapy [41%; n=7056], or triple therapy [13%; n=2286]). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio [95% CI]) with monotherapy (0.68 [0.64-0.71]), dual therapy (0.56 [0.53-0.59]), and triple therapy (0.45 [0.41-0.50]). Nearly half (46%) of patients who received post-discharge medication had no dose escalation. Overall, 59% of patients had follow-up with a primary care physician within 14 days of discharge, and 23% had follow-up with a cardiologist. Conclusions In real-world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline-recommended dual and triple HF therapy remained low. There are opportunities to improve post-discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post-discharge follow-up with providers.

Indexed as

Adrenergic beta-AntagonistsAftercareAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDrug Therapy, CombinationFemaleGuideline AdherenceHeart FailureHumansMaleMineralocorticoid Receptor AntagonistsNeprilysinPatient ReadmissionRetrospective StudiesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsNeprilysinheart failure (with reduced ejection fraction)mortalityoutcomesrehospitalizationtreatment intensity

Identifiers

PMID32805181
PMCPMC7660806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.